Cicor Technologies (CICN) Investor Presentation summary

Strategic focus and market positioning

• Focus on Industrial, Medical, and Aerospace & Defence sectors, representing 84% of 2024 pro forma sales.

• European market leader in Aerospace & Defence electronics manufacturing services after recent acquisitions.

• Fourth largest in Europe for medical device contract development and manufacturing.

• Buy-and-build strategy since 2021, with multiple acquisitions expanding presence and capabilities.

• Emphasis on miniaturization, automation, and advanced technology solutions across sectors.

Financial performance and growth

• Sales grew 24.5% in 2023 to CHF 390 million, with 11.1% organic growth.

• EBITDA margin reached 11.6% in 2023, among the highest in the peer group.

• 2024 guidance targets CHF 460–500 million in sales and 10–13% EBITDA margin.

• Underlying 2023 net earnings per share at CHF 4.19.

• Book-to-bill rate of 1.03 maintained despite recessionary environment.

Sector-specific highlights

• Aerospace & Defence: 23% of 2024 pro forma sales, with solutions for aircraft, satellites, and defense systems.

• Medical: 25% of 2024 pro forma sales, supporting applications like hearing aids, surgical robots, and smart drug delivery.

• Industrial: 37% of 2024 pro forma sales, driving innovation in robotics, sensors, and semiconductor equipment.

• Notable projects include communications masts for Royal Navy frigates and PCBs for NASA's Mars rover.

• Advanced manufacturing capabilities and one-stop-shop services across all sectors.